Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Moderna, Inc. (MRNA) vs PayPal Holdings, Inc. (PYPL) Price & Performance

Moderna, Inc.Trade
PayPal Holdings, Inc.Trade

Price performance (Past 24H)

Key statistics

Moderna, Inc. vs PayPal Holdings, Inc. — how do they compare? Moderna, Inc. trades at $60.53 (market cap $23.88B), while PayPal Holdings, Inc. trades at $58.87 (market cap $50.53B). The key difference: PayPal Holdings, Inc. is far larger — about 2.1× Moderna, Inc.'s market cap, and PayPal Holdings, Inc. pays a 0.95% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

MRNAPYPL
Market Cap
$23.88B$50.53B
Sector
HealthFinancials
52-Week High
$81.80$76.13
52-Week Low
$22.36$39.08
Enterprise Value
$20.03B$52.68B
Dividend Yield
0.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Moderna, Inc.

Moderna (MRNA) stock trades at $59.17, up 9.86% recently, with a bullish technical signal and strong institutional buying interest. The company's Q2 2026 earnings beat expectations, and the FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50+ marks a key post-pandemic milestone. However, fundamentals show declining revenue from $18.9B in 2022 to $1.9B in 2025 and persistent net losses, with a negative net income margin of -142.58% in 2025.

The outlook hinges on pipeline execution; while new vaccine approvals and cost-cutting efforts offer growth potential, the stock faces risks from high valuation multiples and ongoing profitability challenges. Analyst consensus is cautious with a $54.33 price target below the current price, reflecting mixed sentiment amid transitional phase uncertainties.

PayPal Holdings, Inc.

PayPal (PYPL) trades at $59.07, down 1.19% on the day, with a bullish technical outlook supported by moving averages and strong cash flow. Recent earnings beat expectations, with Q2 2026 EPS of $1.38 exceeding the $1.28 consensus, while revenue grew 4.8% year-over-year. The company raised full-year 2026 guidance, signaling confidence in its turnaround under new leadership, amid acquisition interest from Stripe and Advent International at a $53 billion valuation rejected by the board.

PYPL presents a value opportunity with a low P/E of 11.17 and robust free cash flow, but faces risks from competitive pressures and economic sensitivity. Analyst consensus is mixed with 35.7% buy ratings, though institutional buying and undervaluation narratives support upside potential if execution improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA

About PayPal Holdings, Inc.

PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.

Read more on PYPL